Mirum Pharma 2025 sales $521M (+55% YoY); guides 2026 $630-650M; multiple pipeline readouts in 2026

Mirum Pharmaceuticals, Inc.

2025-FY EPS reported -$0.47 revenue$521,312,000

2025 net product sales $521.3M, up from $336.4M in 2024 (+55% YoY). LIVMARLI US sales $244.7M (+69% YoY).
2026 guidance: global net product sales $630-650M, reflecting continued growth.
Pipeline catalysts: Volixibat VISTAS (PSC) topline Q2 2026; Livmarli EXPAND data Q4 2026; Brelovitug HDV data H2 2026.
Completed acquisition of Bluejay Therapeutics for brelovitug; raised $268.5M in private placements.
Cash and investments $391.4M as of Dec 31, 2025; operating expenses $543.4M (incl. $95M non-cash).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.